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pharmaceutical expenditure for patients with hypertension. RESULTS: Pharma-
ceutical expenditures increased with age and the duration of hypertension. A
mixed effect model indicated that being widowed or separated significantly in-
creased pharmaceutical expenditures by $219.12 (P0.0001) and $206.84 (P0.0001)
respectively; the pharmaceutical expenditures decreases by $2.79 (P0.01) if BMI
decreased by 1 kg/m2 from survey round 3 to round 5. Pharmaceutical expenditures
decreased with family size and education level. Compared with the uninsured,
those with public insurance spent $208.33 (P0.0001) more, and those with private
insurance spent $121.01 (P0.0001)more on prescribed medicine for essential
hypertension. CONCLUSIONS: Age, duration of hypertension, marriage status,
BMI, type of insurance, and education were found as significant determinants of
pharmaceutical expenditures for patients with hypertension.
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OBJECTIVES: To investigate the association between blood pressure (BP) control
and healthcare utilization and costs in newly treated patientswith hypertension in
a managed care organization. METHODS: Patients who met the selection criteria
were identified from a healthcare organization during July 2005 – May 2008: 1) age
18; 2) 1 diagnosis of hypertension; 3) 1 prescription for hypertension; 4) con-
tinuously eligible with the organization 6 months before and 12 months after the
initiation of the antihypertensive agent(s) (index date); and 5) 2 blood pressure
(BP) readings with 1 at the index date, and another measured over 90 days of
receivingmedications. Patientswere classified into BP at goal vsersus BP not at goal
by the mean BP during 90 to 365 days after the index date. BP goal is defined as
140/90mmHg for hypertensive patientswithout diabetes, and130/80mmHg for
hypertensive patients with diabetes. Health care utilization and costs for the 12-
month post index date were compared between groups. RESULTS: We identified
1056 patients, themean age was 63 years old, and 54%were females. Overall, there
were 61% of the patients with BP at goal and 36% of the patients with comorbid
hypertension and diabetes met BP goal. The patients who met BP goal had higher
number of outpatient visits (19.0 vs. 14.0; p0.001), higher prescription fills (31.0 vs.
25.0; p0.001), and higher total costs ($7016 vs. $4628; p0.001) than those not at
goal. CONCLUSIONS: To achieve BP goal, physicians would have to follow-up with
patients frequently and emphasize the benefits ofmaintaining BP to goal. Although
the economic benefits of BP control is not immediately seen in the first year treat-
ment in this study, other studies have shown that long term control does prevent
the complications of hypertension, and demonstrate the long term economic ben-
efits. Additional research is warranted.
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OBJECTIVES: To analyze the structure of expenses associated with warfarin dose
adjustment and consequent international normalized ratio (INR) monitoring for
effective stroke prevention in patients with atrial fibrillation.METHODS: The pres-
ent study was designed as cost of illness analysis. Expenses associated with INR
monitoring and warfarin dose adjustment were calculated for four different cir-
cumstances: 1) for obligatorymedical insurance system according the current gen-
eral tariff agreement; 2) for patients managed in outpatient department of Univer-
sity hospital using prices for consultations and coagulation tests; 3) for those
controlling INR in commercial laboratory using their price list; and 4) for self-
monitored patients using costs for coagulomether and test strips purchasing.
RESULTS:Within the obligatory medical insurance system total expenses for war-
farin management accounted for 4058 Roubles/person per year, but share of ex-
penses for warfarin purchasingwas less than 1%; for patients treated in outpatient
department of University clinic that estimated for 13019 Roubles/person per year
and 0.03%; in the case of INR control in commercial laboratory – 18648 Roubles/
person per year and 0.02%; and for self-moniroring – from 40,405 Roubles/person
per year (0.01%) in the first year (that includes the fee for coagulomether purchas-
ing) to 7405 Roubles/person per year (0.05%) in consequent years respectively.
CONCLUSIONS: Regardless the strategy of INR control, concomitant expenses as-
sociated with warfarin dose adjustment and subsequent efficiency and safety
monitoring is more than 100-fold higher than the price of warfarin itself.
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OBJECTIVES:One of themajor complications aftermajor orthopedic surgery (OS) is
Venous Thromboembolism (VTE). VTE is an important condition not only because
of the potential long term complications to patients, but also the cost burden it
brings to the society. Unfortunately, no data readily exists showing the cost of VTE
prophylaxis (VTEp) in Turkey. Therefore, this study calculates the diagnosis and
treatment costs of VTEp aftermajor OS based on expert opinion.METHODS:Health
Economists of BayerTürk created a survey to a)determine the resources utilized in
diagnosis and treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism
(PE), b)establish the costs corresponding to potential complications of VTEp; intra
cerebral hemorrhages (ICH) and gastrointestinal bleeds (GIB) The survey was com-
pleted by the pioneers in Orthopedics and Traumatology, cardiovascular diseases,
hematology, gastroenterology, neurology and pulmonary diseases, based on daily
clinical practice and guidelines. An Expert Panel preceded the completion of sur-
veys, during which a consensus is reached. Based on the consensus, the costs of
VTEp are calculated from payer’s perspective. RESULTS: According to expert opin-
ion, there are approximately 20,000-30,000 TKR, 25,000-30,000 THR surgeries are
performed annually in Turkey. The major bleeding rates among these patients is
approximately 1%, half of them being ICH and the other half being GIB. Ddiagnosis
and treatment costs of VTEp and major bleeds calculated based on expert opinion
are: a)Diagnosis cost of DVT (PE): TL 33 (48) for inpatients and TL 126 (150) for
outpatients, b)Treatment cost of DVT (PE): TL 372 (1177) if hospitalization is re-
quired and TL 162 (757) if not, c)Diagnosis cost of ICH (GIB): TL 81 (192), d)Treatment
cost of ICH (GIB): TL 682 (537). CONCLUSIONS: This study displays the importance
of VTE prophylaxis. Diagnosis and treatment of VTE creates disease and cost bur-
den to the public and the society.
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OBJECTIVES:Orthopedic surgery presents a high risk of venous thromboembolism
(VTE). Without prophylaxis, between 41% and 85% of patients who undergo high-
risk orthopedic procedures develop deep vein thrombosis (DVT) and up to 10%
develop pulmonary embolism (PE). Furthermore, the economic burden of VTE is
perceived as substantially high in Colombia. Few data on the total economic bur-
den of DVT and PE associated to orthopedic surgery, however, is available in the
country. The objective of this study was to quantify the economic burden of DVT
and PE in the Colombian health care setting.METHODS:Delphi Panelmethodology
was used to estimate 2011 resource utilization associated with VTE treatment
events in patients undergoing hip and knee replacement. Delphi Panel contained
specialists from the private Colombian setting. Local available databases and pub-
lished literature was retrieved. Cost estimations (inpatient and outpatient costs,
acquisition costs, bleedings costs, intracranial hemorrhages and other associated
costs) considered the private perspective, using unit cost data from Seguro Obliga-
torio de Accidentes de Tránsito (SOAT). RESULTS: In Colombia the cost of hip
replacement surgery (in 2011USD)was estimated at USD $3182 and the cost of knee
replacement at USD$2942. Mean symptomatic PE costs for inpatients with hip
replacement was USD$6651 and DVT mean costs was USD$4061. Cost of treating
minor bleeding adverse events in patients with hip replacement, was estimated as
USD$4157 andmajor bleeding as USD$6171. Themean symptomatic PE costs (2011
US$) for inpatients with knee replacement was USD$6538 and DVTwas USD $3801.
Cost of treating minor bleeding adverse events in patients with knee replacement,
was estimated as USD$3931 andmajor bleeding as USD$5945. CONCLUSIONS: The
occurrence of VTE events related to orthopedic surgery can significantly impact
overall costs of orthopedic surgery in Colombia.
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OBJECTIVES: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are clini-
cal manifestations of VTE that can occur with or without symptoms. A major risk
factor for VTE is orthopedic surgery. The economic burden of recurrent VTE asso-
ciated to hip and knee replacement is perceived as considerable high within the
Argentinean health care system; however, the data supporting this perception is
scarce. The objective of this study is to document the health care resource utiliza-
tion and costs associatedwith the care of VTEp and its complications related to hip
and knee replacement in Argentina. METHODS: Data regarding health care re-
sources associated with the treatment of VTE and major and minor bleeding was
estimated using Delphi panel methodology in 2011 (specialists from public and
private settings); locally available databases and published literature. Costs esti-
mations (inpatient and outpatient costs, acquisition costs, bleedings costs, intra-
cranial hemorrhages and other associated costs) considered a weighted average of
three different perspectives: 1) private; 2) public health care system; and 3) social
insurance. Costs are reported in 2011 USD. RESULTS: The estimated mean cost -if
events occur while hip replacement inpatient surgery- of treating symptomatic PE
is approximately USD$4510while the cost of DVTwas estimated inUSD $2904. Cost
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